The 4-TRLs signature is a tool that can be applied in HCC clinical practice. It enables prognostic stratification and helps guide treatment. These lncRNAs are linked to both immune activity and drug response. This dual role shows they affect tumor progression and the microenvironment. This finding provides new insights for precision oncology in HCC.
Yang et al. (Fri,) studied this question.